Comparing DNA Microarray Platforms for Breast Tumor Analysis
Author Information
Author(s): Baumbusch LO, Aarøe J, Johansen FE, Hicks J, Sun H, Bruhn L, Gunderson K, Naume B, Kristensen VN, Liestøl K, Børresen-Dale A-L, Lingjærde OC
Primary Institution: Norwegian Radium Hospital, Rikshospitalet University Hospital
Hypothesis
How do different DNA microarray platforms compare in detecting copy number alterations in breast tumors?
Conclusion
Different DNA microarray platforms reveal similar patterns of genomic alterations in breast tumors, but some unique changes are only detected by specific platforms.
Supporting Evidence
- All platforms showed high overall concordance in detecting common aberrations.
- Unique amplification peaks were detected by specific platforms.
- Correlation analysis indicated higher similarity between ROMA/NimbleGen and Illumina.
Takeaway
Scientists looked at breast cancer samples using three different tools to see how well they could find changes in DNA. They found that while all tools showed similar results, some changes were only seen by one tool.
Methodology
The study compared three DNA microarray platforms using 20 breast tumor samples and various statistical methods to analyze copy number changes.
Limitations
Some unique amplifications and deletions were not detected by all platforms, indicating potential limitations in sensitivity.
Participant Demographics
The samples included 20 breast carcinomas with >40% tumor cells, primarily stage I and II tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website